Search PubMed⌕ Search

Biomedical subjects

R Yamada

Publications and source records attributed to R Yamada.

At least 289 records · Page 16Linked to original sources
PubMed1983

[Hepatic artery embolization therapy for advanced hepatoma].

A total of 244 cases of hepatoma was subjected to hepatic artery embolization, and the 1-year, 2-year and 3-year cumulative survival rates were 45%, 27% and 12% respectively. The one year survival rate was far higher than the corresponding rate (7%) of intrahepatic arterial chemotherapy. The human livers which were autopsied or resected after the embolization were examined histologically. In 3 cases with main portal vein occlusion due to tumor thrombi, not only tumor tissue but also surrounding liver tissue were affected by extensive necrosis. But in 4 cases with patency of portal vein and severe liver cirrhosis, no necrotic region was detected in the liver parenchyma. Four of the seven patients who had been alive for more than 3 years after the therapy were accompanied with severe liver cirrhosis. It is suggested that liver cirrhosis is not so harmful factor in hepatic artery embolization therapy for advanced hepatoma.

Adult↗
PubMed1983

[The effect of preoperative embolization of Wilms' tumor].

The case was a 2-year and 11-month-old boy with Wilms' tumor. Preoperative embolization using gelatin sponge was performed after diagnosis of aortography. Immediately after the treatment, tumor size and vascularity were reduced remarkably. Nephrectomy was carried out without remarkable bleeding and the tumor was removed easily.

Child, Preschool↗
PubMed1983

Antivitamin B6 activity of L-penicillamine in Escherichia coli.

Escherichia coli wild strain K12 and the vitamin B6 requiring mutant strain KG980 were compared with respect to the growth inhibition by L-penicillamine and the reversal of inhibition with pyridoxine. The growth of KG980 was much more severely inhibited than that of K12 by relatively low concentrations of L-penicillamine, when KG980 was grown with a usually sufficient concentration of pyridoxine. The following findings indicated that this was because L-penicillamine caused vitamin B6 deficiency in KG980; (a) addition of excess pyridoxine significantly reversed the inhibition, (b) comparison of the growth with various concentrations of pyridoxine showed that the vitamin requirement became higher upon addition of L-penicillamine. Examination of cellular vitamin B6 compounds showed that pyridoxal 5'-phosphate was markedly decreased when L-penicillamine was present, in agreement with the probable reaction of the inhibitor with the coenzyme. On the other hand, the growth inhibition of K12 appeared independent of vitamin B6 deficiency, and the cellular pyridoxal 5,-phosphate was found not to be markedly reduced by the presence of L-penicillamine, while the total of vitamin B6 compounds, probably including the product formed by the coenzyme and the inhibitor, increased clearly. The results, therefore, suggest that the wild strain of E. coli can avoid the deficiency of vitamin B6 by enhancing its biosynthesis, although L-penicillamine acts as an antivitamin B6.

Escherichia coli↗
PubMed1982

A comparison of transcatheter arterial embolization with one shot therapy for the patients with hepatic cell carcinoma.

It has been confirmed gradually that transcatheter arterial embolization is the most effective, conservative therapy for the treatment of unresectable hepatic cell carcinoma (hepatoma). Embolization or one shot therapy was carried out in a clinical trial involving 41 patients with unresectable hepatoma visiting our department. Embolization group (emboli G): 19 cases. 1 to 6 embolizations in each case. One shot group (one shot G): 22 cases. Medications: Mitomycin C 10-40 mg and others. Disappearance rate of icterus after treatment was 50% (emboli G) and 25% (one shot G). Decrease in size of hepatomegaly or tumor was seen in 84% (emboli G) and 32% (one shot G) which was statistically significant (less than 1%). Serum AFP titer after embolization decreased in all cases but in only 5 of 12 cases (ca 41%) after one shot (less than 1%). Effective cases measured by Karnofsky's method were 18 out of 19 cases (95%) in emboli G, but in one shot G only 10 out of 22 cases (ca 45%)(less than 0.1%). Survival rate after each therapy was 67% (emboli G) and 38% (one shot G) after 6 months, and 59% (emboli G) and 19% (one shot G) at 1 year respectively. One study showed that transcatheter arterial embolization therapy was much more effective than one shot therapy.

Adult↗